Evaluating the Impact of Pharmacists in Medication Therapy Management for Chronic Diseases
Keywords:
Medication Therapy Management, chronic diseases, pharmacist-led interventions, patient satisfaction, healthcare utilization, clinical outcomesAbstract
Background: Pharmacists-led Medication Therapy Management (MTM) services have been identified as an effective intervention for managing chronic disease. The impact of pharmacist-led MTM on clinical outcomes, healthcare utilization, patient satisfaction, and cost savings for patients with chronic conditions is evaluated in the study.
Objectives: The main goal was to evaluate the impact of MTM interventions on clinical indicators ( HbA1c, blood pressure), healthcare resource utilization, and patient satisfaction in patients with chronic diseases ( diabetes and hypertension).
Methods: Patients with chronic diseases who received pharmacist-led MTM interventions were the subjects of the observational study. Before the intervention, we collected clinical data and healthcare utilization rates (readmissions and emergency visits) as well as patient satisfaction scores. Descriptive statistics and paired t-tests were used to find significant changes, in data, in outcomes.
Results: We found that clinical indicators improved greatly, HbA1c reduced from 8.5% to 7.3%, and blood pressure from 145/90 mmHg to 130/85 mmHg. In addition, healthcare utilization decreased due to 12 percent to 6 percent fewer hospital readmissions. Significant increases in patient satisfaction scores from 3.2 to 4.5 on a 5-point scale were seen. According to economic analysis, healthcare costs were reduced, especially medication and emergency room costs.
Conclusion: In chronic disease management, pharmacist-led MTM interventions significantly improve clinical outcomes, reduce healthcare utilization, and improve patient satisfaction. These results demonstrate the value of MTM services to enhance patient care, lower healthcare costs, and enhance patient quality of life.
Downloads
Metrics
References
Viswanathan M, Kahwati LC, Golin CE, Blalock SJ, Coker-Schwimmer E, Posey R, Lohr KN. Medication therapy management interventions in outpatient settings: a systematic review and meta-analysis. JAMA Internal Medicine. 2015 Jan 1;175(1):76-87.
Bunting BA, Cranor CW. The Asheville Project: long-term clinical, humanistic, and economic outcomes of a community-based medication therapy management program for asthma. Journal of the American Pharmacists Association. 2006 Mar 1;46(2):133-47.
Balas M, Plakogiannis R, Sinnett M. Periorbital edema associated with separate courses of ibuprofen and naproxen. American Journal of Health-System Pharmacy. 2010 Jun 1;67(11):906-9.
Giberson S, Yoder S, Lee MP. Improving patient and health system outcomes through advanced pharmacy practice. A Report to the US Surgeon General. Office of the Chief Pharmacist. US Public Health Service. 2011 Dec 1;44.
Cochran G, Hruschak V, Bacci JL, Hohmeier KC, Tarter R. Behavioral, mental, and physical health characteristics and opioid medication misuse among community pharmacy patients: a latent class analysis. Research in Social and Administrative Pharmacy. 2017 Nov 1;13(6):1055-61.
Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti–TNF-α agents. Jama. 2009 Feb 18;301(7):737-44.
Burns A. Medication therapy management in pharmacy practice: core elements of an MTM service model (version 2.0). Journal of the American Pharmacists Association. 2008 May 1;48(3):341-53.
Bluml BM. Definition of medication therapy management: development of professionwide consensus. Journal of the American Pharmacists Association. 2005 Sep 1;45(5):566-72.
Ramalho de Oliveira D, Brummel AR, Miller DB. Medication therapy management: 10 years of experience in a large integrated healthcare system. Journal of Managed Care Pharmacy. 2010 Apr;16(3):185-95.
Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. American journal of hospital pharmacy. 1990 Mar 1;47(3):533-43.
Dekkers OM, Egger M, Altman DG, Vandenbroucke JP. Distinguishing case series from cohort studies. Annals of internal medicine. 2012 Jan 3;156(1_Part_1):37-40.
Hui-Callahan BC, Luder HR, Frede SM. Impact of the pay-for-performance-for-patients program for diabetes management. Journal of the American Pharmacists Association. 2013 Nov 1;53(6):644-7.
Altawalbeh SM, Ibrahim IA, Al-Shatnawi SF. Influence of pharmaceutical promotion on prescribers in Jordan. International journal of clinical pharmacy. 2020 Apr;42(2):744-55.
Horne BD, Budge D, Masica AL, Savitz LA, Benuzillo J, Cantu G, Bradshaw A, McCubrey RO, Bair TL, Roberts CA, Rasmusson KD. Early inpatient calculation of laboratory-based 30-day readmission risk scores empowers clinical risk modification during index hospitalization. American Heart Journal. 2017 Mar 1;185:101-9.
Cipolle RJ, Strand LM, Morley PC. Pharmaceutical care practice: the patient-centered approach to medication management. New York: McGraw-Hill Medical; 2012 Apr 22.
Graco M, Hutchinson A, Barker A, Lawlor V, Wong R, Fourlanos S. Glycemic outcome not predicted by baseline psychological measures in a diabetes management program. Population health management. 2012 Jun 1;15(3):163-7.
Chui MA, Stone JA. Exploring information chaos in community pharmacy handoffs. Research in Social and Administrative Pharmacy. 2014 Jan 1;10(1):195-203.
Li C, Ge S, Zhou J, Peng J, Chen J, Dong S, Feng X, Su N, Zhang L, Zhong Y, Deng L. Exploration of the effects of the CYCLOPS gene RBM17 in hepatocellular carcinoma. PloS one. 2020 Jun 4;15(6):e0234062.
Schumann III SO. Improved quality of life and nonspecific symptoms with fixed‐dose combination drugs. The Journal of Clinical Hypertension. 2017 Feb;19(2):135.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
